149 related articles for article (PubMed ID: 32470636)
1. Modulation of immune response and enhanced clearance of Salmonella typhi by delivery of Vi polysaccharide conjugate using PLA nanoparticles.
Meena J; Kumar R; Singh M; Ahmed A; Panda AK
Eur J Pharm Biopharm; 2020 Jul; 152():270-281. PubMed ID: 32470636
[TBL] [Abstract][Full Text] [Related]
2. The influence of conjugation variables on the design and immunogenicity of a glycoconjugate vaccine against Salmonella Typhi.
Arcuri M; Di Benedetto R; Cunningham AF; Saul A; MacLennan CA; Micoli F
PLoS One; 2017; 12(12):e0189100. PubMed ID: 29287062
[TBL] [Abstract][Full Text] [Related]
3. The immunogenic characteristics associated with multivalent display of Vi polysaccharide antigen using biodegradable polymer particles.
Anish C; Goswami DG; Kanchan V; Mathew S; Panda AK
Biomaterials; 2012 Oct; 33(28):6843-57. PubMed ID: 22748669
[TBL] [Abstract][Full Text] [Related]
4. Specific and cross-reactive immune response to oral Salmonella Typhi Ty21a and parenteral Vi capsular polysaccharide typhoid vaccines administered concomitantly.
Pakkanen SH; Kantele JM; Savolainen LE; Rombo L; Kantele A
Vaccine; 2015 Jan; 33(3):451-8. PubMed ID: 25433216
[TBL] [Abstract][Full Text] [Related]
5. First characterization of immunogenic conjugates of Vi negative Salmonella Typhi O-specific polysaccharides with rEPA protein for vaccine development.
Salman M; St Michael F; Ali A; Jabbar A; Cairns C; Hayes AC; Rahman M; Iqbal M; Haque A; Cox AD
J Immunol Methods; 2017 Nov; 450():27-33. PubMed ID: 28735760
[TBL] [Abstract][Full Text] [Related]
6. Immunization with the conjugate vaccine Vi-CRM₁₉₇ against Salmonella typhi induces Vi-specific mucosal and systemic immune responses in mice.
Fiorino F; Ciabattini A; Rondini S; Pozzi G; Martin LB; Medaglini D
Vaccine; 2012 Sep; 30(43):6111-4. PubMed ID: 22705173
[TBL] [Abstract][Full Text] [Related]
7. Multicenter study for the evaluation of the antibody response against salmonella typhi Vi vaccination (EMPATHY) for the diagnosis of Anti-polysaccharide antibody production deficiency in patients with primary immunodeficiency.
Sánchez-Ramón S; de Gracia J; García-Alonso AM; Rodríguez Molina JJ; Melero J; de Andrés A; García Ruiz de Morales JM; Ferreira A; Ocejo-Vinyals JG; Cid JJ; García Martínez JM; Lasheras T; Vargas ML; Gil-Herrera J; García Rodríguez MC; Castañer JL; González Granado LI; Allende LM; Soler-Palacin P; Herráiz L; López Hoyos M; Bellón JM; Silva G; Gurbindo DM; Carbone J; Rodríguez-Sáinz C; Matamoros N; Parker AR; Fernández-Cruz E;
Clin Immunol; 2016 Aug; 169():80-84. PubMed ID: 27236002
[No Abstract] [Full Text] [Related]
8. Development of a synthetic Vi polysaccharide vaccine for typhoid fever.
Ni Y; Springer MJ; Guo J; Finger-Baker I; Wilson JP; Cobb RR; Turner D; Tizard I
Vaccine; 2017 Dec; 35(51):7121-7126. PubMed ID: 29150208
[TBL] [Abstract][Full Text] [Related]
9. Vi Capsular Polysaccharide Produced by Recombinant
Xiong K; Zhu C; Chen Z; Zheng C; Tan Y; Rao X; Cong Y
Front Cell Infect Microbiol; 2017; 7():135. PubMed ID: 28484685
[TBL] [Abstract][Full Text] [Related]
10. Nasal immunization of mice with AFCo1 or AFPL1 plus capsular polysaccharide Vi from Salmonella typhi induces cellular response and memory B and T cell responses.
Romeu B; Lastre M; Reyes L; González E; Borrero Y; Lescaille D; Pérez R; Nuñez D; Pérez O
Vaccine; 2014 Dec; 32(51):6971-6978. PubMed ID: 25454865
[TBL] [Abstract][Full Text] [Related]
11. Constitutive expression of the Vi polysaccharide capsular antigen in attenuated Salmonella enterica serovar typhi oral vaccine strain CVD 909.
Wang JY; Noriega FR; Galen JE; Barry E; Levine MM
Infect Immun; 2000 Aug; 68(8):4647-52. PubMed ID: 10899868
[TBL] [Abstract][Full Text] [Related]
12. Protective efficacy and immunogenicity of Vi-porin conjugate against Salmonella typhi.
Singh M; Ganguly NK; Kumar L; Vohra H
Microbiol Immunol; 1999; 43(6):535-42. PubMed ID: 10480549
[TBL] [Abstract][Full Text] [Related]
13. Oral priming with Salmonella Typhi vaccine strain CVD 909 followed by parenteral boost with the S. Typhi Vi capsular polysaccharide vaccine induces CD27+IgD-S. Typhi-specific IgA and IgG B memory cells in humans.
Wahid R; Pasetti MF; Maciel M; Simon JK; Tacket CO; Levine MM; Sztein MB
Clin Immunol; 2011 Feb; 138(2):187-200. PubMed ID: 21146460
[TBL] [Abstract][Full Text] [Related]
14. Re-examination of immune response and estimation of anti-Vi IgG protective threshold against typhoid fever-based on the efficacy trial of Vi conjugate in young children.
Szu SC; Klugman KP; Hunt S
Vaccine; 2014 Apr; 32(20):2359-63. PubMed ID: 24630869
[TBL] [Abstract][Full Text] [Related]
15. Engineering, conjugation, and immunogenicity assessment of Escherichia coli O121 O antigen for its potential use as a typhoid vaccine component.
Wetter M; Kowarik M; Steffen M; Carranza P; Corradin G; Wacker M
Glycoconj J; 2013 Jul; 30(5):511-22. PubMed ID: 23053636
[TBL] [Abstract][Full Text] [Related]
16. A bivalent conjugate vaccine containing PspA families 1 and 2 has the potential to protect against a wide range of Streptococcus pneumoniae strains and Salmonella Typhi.
Kothari N; Kothari S; Choi YJ; Dey A; Briles DE; Rhee DK; Carbis R
Vaccine; 2015 Feb; 33(6):783-8. PubMed ID: 25545593
[TBL] [Abstract][Full Text] [Related]
17. Immune suppression induced by Vi capsular polysaccharide is overcome by Vi-DT conjugate vaccine.
An SJ; Yoon YK; Kothari S; Kim DR; Kim JA; Kothari N; Lee E; Park TH; Carbis R
Vaccine; 2012 Feb; 30(6):1023-8. PubMed ID: 22192846
[TBL] [Abstract][Full Text] [Related]
18. Head-to-head comparison of humoral immune responses to Vi capsular polysaccharide and Salmonella Typhi Ty21a typhoid vaccines--a randomized trial.
Kantele A; Pakkanen SH; Karttunen R; Kantele JM
PLoS One; 2013; 8(4):e60583. PubMed ID: 23593253
[TBL] [Abstract][Full Text] [Related]
19. Differential Killing of Salmonella enterica Serovar Typhi by Antibodies Targeting Vi and Lipopolysaccharide O:9 Antigen.
Hart PJ; O'Shaughnessy CM; Siggins MK; Bobat S; Kingsley RA; Goulding DA; Crump JA; Reyburn H; Micoli F; Dougan G; Cunningham AF; MacLennan CA
PLoS One; 2016; 11(1):e0145945. PubMed ID: 26741681
[TBL] [Abstract][Full Text] [Related]
20. Development of a bead immunoassay to measure Vi polysaccharide-specific serum IgG after vaccination with the Salmonella enterica serovar Typhi Vi polysaccharide.
Staats HF; Kirwan SM; Whisnant CC; Stephenson JL; Wagener DK; Majumder PP
Clin Vaccine Immunol; 2010 Mar; 17(3):412-9. PubMed ID: 20107010
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
